Iain Gladstone Ross is a British businessperson who founded Biomer Technology Ltd. and who has been at the head of 19 different companies. Presently, he holds the position of Chairman for Kazia Therapeutics Ltd., Non-Executive Chairman of ReNeuron Group Plc, Non-Executive Chairman for Silence Therapeutics Plc, Chairman of Biomer Technology Ltd., Non-Executive Chairman for Motif Bio Plc, Chairman at Novagen Ltd. and Non-Executive Chairman at BiVictriX Therapeutics Plc. Iain Gladstone Ross is also on the board of Palla Pharma Ltd., Redx Oncology Ltd. and Gladstone Partners Ltd.
In the past Mr. Ross was Non-Executive Chairman at Smartspace Software Plc, Non-Executive Chairman of e-Therapeutics Plc, Executive Chairman for Silence Therapeutics Plc, Non-Executive Chairman of Pharminox Ltd, Non-Executive Director at Premier Veterinary Group Plc and Non-Executive Chairman for Ark Therapeutics Group Plc (a subsidiary of Premier Veterinary Group Plc), Chairman & Chief Executive Officer for Sandoz AG, Non-Executive Chairman for Redx Pharma Plc, Chief Executive Officer of Reed Business Information Ltd., Chief Executive Officer at Lonza Biologics Plc, Chief Executive Officer for Hoffman-La Roche, Inc., Chief Executive Officer of Quadrant Healthcare Plc, Principal at Fisons Plc, Vice Chairman-Council of Royal Holloway at the University of London, Vice Chairman-Council at Royal Holloway University of London and Chartered Director at The Institute of Directors (United Kingdom).
Iain Gladstone Ross received an undergraduate degree from the University of London.